Merck & Company Inc (MRK)

$120.00

up-down-arrow $-0.76 (-0.63%)

As on 12-Jun-2026 13:48EDT

Market cap

info icon

$298,256 Mln

Revenue (TTM)

info icon

$65,593 Mln

P/E Ratio

info icon

34

P/B Ratio

info icon

6.4

Div. Yield

info icon

2.8 %

Merck & Company Inc (MRK) Share Price

Compare

High:loading Low:loading Return: loading

Max:loading Min:loading Median:loading

Max:loading Min:loading Median:loading

loading...
loading...
loading...
loading...
loading...
loading...
loading...
loading...

Stock Range

Today’s Range

Low: 119.67 High: 121.90

52 Week Range

Low: 76.66 High: 125.14

Liquidityliquidity Low

Low Moderate High

Fundamentals

  • Net Profit (TTM)Net Profit (TTM) information

    $13,175 Mln

  • ROEROE information

    0.2 %

  • ROCEROCE information

    19.4 %

  • Industry P/EIndustry P/E information

    30.86

  • EV/EBITDAEV/EBITDA information

    17.4

  • Debt to EquityDebt to Equity information

    1

  • Book ValueBook Value information

    $18.6

  • EPSEPS information

    $3.6

  • Face valueFace value information

    --

  • Shares outstandingShares outstanding information

    2,469,824,415

10 Years Aggregate

CFO

$117,929.00 Mln

EBITDA

$115,983.00 Mln

Net Profit

$75,684.00 Mln

Performance

Company
YTD
1 Month
3 Months
1 Year
3 Years
5 Years
10 Years
Merck & Company Inc (MRK)
14.0 7.8 3.3 49.4 2.7 9.5 8.3
BSE Sensex
-10.8 -0.6 -1.7 -8.5 6.4 7.6 11.0
S&P Small-Cap 600#
-5.8 -5.3 -13.7 -6.3 5.3 3.0 5.5
As on 12-Jun-2026  |  #As on 26-Oct-2023
Company
2025
2024
2023
2022
2021
2020
2019
Merck & Company Inc (MRK)
5.8 -8.7 -1.7 44.8 1.9 -7.1 22.4
S&P Small-Cap 600
4.0 7.0 13.9 -17.4 25.3 9.6 20.9
BSE Sensex
9.1 8.1 18.7 4.4 22.0 15.8 14.4

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details
loading...

*All values are in ($ Mln)

loading...

*All values are in ($ Mln)

loading...

*All values are in ($ Mln)

Key Ratios

View Details
loading...

loading...

loading...

5Y Avg -- 3Y Avg -- TTM --

loading...

P/E Ratio

--

--Min --Median --Max

loading...

P/B Ratio

--

--Min --Median --Max

loading...

Earnings Yield (%)

--

Earnings Yield (%) = EBIT / Enterprise value

PEG Ratio

--

Price = Price / Earnings to growth ratio

loading...

loading...

loading...

Peers

View Details
Company
Price ($) Market Cap ($ Mln) Revenue (TTM) Net Profit (TTM) OPM (%) ROE (%) P/E P/B
Merck & Company Inc (MRK)
120.0 298,256.0 65,593.0 8,935.0 24.7 18.3 34 6.4
354.9 188,671.2 37,238.0 7,800.0 29.1 82.9 24.3 20.5
200.9 28,839.4 9,857.4 1,372.4 19.3 7.4 21 1.5
57.1 116,663.5 48,482.0 7,275.0 21.6 37.7 16 5.8
224.1 52,427.0 250,549.0 1,559.0 0.9 -- 34.1 16.1
125.5 160,361.2 29,734.0 9,216.0 39.5 40.9 17.6 6.8
789.5 94,623.4 403,430.0 4,762.0 1.6 -246.4 20.5 5.0
153.5 293,693.5 56,053.0 13,533.8 30.3 32.7 22.1 7.6
26.2 149,154.5 63,315.0 7,491.0 16.7 8.1 20 1.6
80.3 33,358.0 9,509.0 2,643.0 37.3 61.2 13 10.3

Shareholding Pattern

View Details
loading...
These are advertorial stories which keeps Value Research free for all. Click here to mark your interest for an ad-free experience in a paid plan

About Merck & Company Inc (MRK)

Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23,...  Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. has strategic collaboration with Infinimmune, Inc. to discover and develop antibodies against multiple therapeutic targets. The company was founded in 1891 and is headquartered in Rahway, New Jersey. 

  • Chairman, President & CEO

    Mr. Robert M. Davis J.D.

  • Chairman, President & CEO

    Mr. Robert M. Davis J.D.

  • Headquarters

    Rahway, NJ

  • Website

    https://www.merck.com

Edit peer-selector-edit
loading...
loading...

FAQs for Merck & Company Inc (MRK)

The share price of Merck & Company Inc (MRK) is $120.00 (NYSE) as of 12-Jun-2026 13:48 EDT. Merck & Company Inc (MRK) has given a return of 2.72% in the last 3 years.

The P/E ratio of Merck & Company Inc (MRK) is 34.02 times as on 12-Jun-2026, a 10 premium to its peers’ median range of 30.86 times.
The P/B ratio of Merck & Company Inc (MRK) is 6.41 times as on 12-Jun-2026, a 11 premium to its peers’ median range of 5.79 times.


PE & PB ratio at the end of financial year.


Year P/E Ratio P/B Ratio
2025
14.35
4.98
2024
14.77
5.46
2023
762.89
7.41
2022
19.47
6.15
2021
14.89
5.09

The 52-week high and low of Merck & Company Inc (MRK) are Rs 125.14 and Rs 76.66 as of 14-Jun-2026.

Merck & Company Inc (MRK) has a market capitalisation of $ 298,256 Mln as on 12-Jun-2026. As per SEBI classification, it is a Small Cap company.

Before investing in Merck & Company Inc (MRK), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.

For guidance, explore our expert-curated portfolios and Stock recommendations with Value Research Stock Advisor.
Want to explore on your own? Click here to see how this stock scores on quality, growth, valuation, and momentum.